Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase III, Clinical Trial Comparing the Persistence of GSK Biologicals New Adjuvanted Hepatitis B Vaccine to a Double Dose of Engerix™-B at Months 24, 30, 36, in Pre-haemodialysis/Haemodialysis Patients (≥15 Years of Age)

NCT00383591 is registered in ClinicalTrials.gov with GlaxoSmithKline as lead sponsor.

NCT NCT00383591
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00383591 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase III, Clinical Trial Comparing the Persistence of GSK Biologicals New Adjuvanted Hepatitis B Vaccine to a Double Dose of Engerix™-B at Months 24, 30, 36, in Pre-haemodialysis/Haemodialysis Patients (≥15 Years of Age)
Lead sponsor
GlaxoSmithKline
Phase
Phase 3
Overall status
Completed
Start date
March 31, 2002
Completion date
January 31, 2004
Enrollment
120
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

hepatitis b